Navigation Links
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
Date:7/14/2008

PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 10th Biennial FASEB Summer Research Conference Protein Phosphatases in Snowmass Village, Colorado. The poster presentation entitled, "Trodusquemine (MSI-1436), An Allosteric Inhibitor of Protein Tyrosine Phosphatase 1B," concluded that MSI-1436 is a selective, reversible and noncompetitive inhibitor of PTP-1B that enhances insulin signaling through potent PTP-1B inhibition both in vivo and in vitro.

"The search to discover PTP-1B inhibitors as a therapeutic target for the treatment of obesity and type 2 diabetes has long been a goal of drug development but achieving the selectivity necessary to demonstrate safety has been a significant hurdle. The new information on the mechanism by which MSI-1436 inhibits PTP-1B supports its first-in-class status," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "MSI-1436 is the only reversible, noncompetitive inhibitor of PTP-1B in clinical stage development. It is the allosteric nature of MSI-1436 and its ability to reversibly inhibit PTP-1B that is believed to be the key to the safety we have observed in Phase 1. We anticipate this will be attractive to both potential partners and clinicians as we obtain further evidence of the efficacy and safety of MSI-1436 in future studies."

Inhibition of PTP-1B, a non-receptor isoform of the protein tyrosine phosphatase family, by MSI-1436 has been shown to reduce food intake, induce weight loss, and increase insulin sensitivity
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
2. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, ... medical device company developing its Symphony® CGM System ... today announced that Robert F. Doman , ... will present at "TEN", Noble Financial Capital Markets, ... Doman will make a corporate presentation to prospective ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... S.r.l. a full service and,leading clinical research organization (CRO), ... Research S.r.l., a CRO focused on Phase I to,Phase ... http://www.newscom.com/cgi-bin/prnh/20080122/335477 ) , ... and have legal and,operating offices in Milan, Italy. The ...
... DIO Rats Highlighted -PLYMOUTH MEETING, Pa., Jan. 22 ... GENR ) today announced a poster presentation ... drug candidate for the treatment of type 2 ... - Novel Aspects of the Regulation of Body ...
Cached Medicine Technology:Phidea Srl and Marvin Research Srl Announce Completion of Merger 2Phidea Srl and Marvin Research Srl Announce Completion of Merger 3Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and Soothes Young Throats Now Available,Across the Northern ... cough and cold season,rapidly approaches, Integrated Beverage Group, ... products has launched its newest product,in Canada -- ... a perfect choice for parents who wish to,choose ...
... Company to Serve About 50,000 People Beginning February 1, ... AMERIGROUP,Corporation (NYSE: AGP ) announced today that the ... authorizing the Company,s Nevada subsidiary to,enter that State,s Medicaid ... 2009., The Nevada State Board of Examiners has ...
... lead to new treatments, researchers say , , WEDNESDAY, Nov. ... cells exhausted from fighting HIV infection has been discovered ... a molecule called Tim-3 is present at high levels ... HIV, the virus that causes AIDS. Blocking the activity ...
... Expertise to ... ... the,election of Jay Parsons to the company,s board of directors effective,immediately., ... programs and the development of customized incentive programs,that help consumers make ...
... likely to skip medicines, compared to whites , , WEDNESDAY, ... that included encouragement and occasional gifts improved medication adherence ... Americans with high blood pressure, a new study found. ... be nearly twice as likely to not take their ...
... That Demonstrate Best Strategic Use of Mergers ... ... Deal,( http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare ... honored Abbott for the,most effective strategic use of acquisitions and divestitures., ...
Cached Medicine News:Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 2Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 4Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:MedVantx(R) Names Newest Board Member 2Health News:Education Program Spurs Blacks to Take Blood Pressure Meds 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... automated genetic analysis system. This system automatically ... linear polyacrylamide (LPA) gel, denatures and loads ... analyzes the data. Software tools let you ... automated data assessment. All to ensure unprecedented ...
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
Medicine Products: